MCID: BRN012
MIFTS: 60

Bronchiolitis Obliterans

Categories: Rare diseases, Respiratory diseases

Aliases & Classifications for Bronchiolitis Obliterans

MalaCards integrated aliases for Bronchiolitis Obliterans:

Name: Bronchiolitis Obliterans 38 12 53 55 44 15 73
Obliterative Bronchiolitis 12 53 37
Bronchiolitis Fibrosa Obliterans 12 73
Bronchiolitis, Exudative 73
Bronchiolitis Exudativa 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2799
MeSH 44 D001989
NCIt 50 C62580
SNOMED-CT 68 31886003 40100001
KEGG 37 H01873

Summaries for Bronchiolitis Obliterans

NIH Rare Diseases : 53 Bronchiolitis obliterans is an inflammatory condition that affects the lung's tiniest airways, the bronchioles. In affected people, the bronchioles may become damaged and inflamed leading to extensive scarring that blocks the airways. Signs and symptoms of the condition include a dry cough; shortness of breath; and/or fatigue and wheezing in the absence of a cold or asthma. Many different chemicals (such as nitrogen oxides, ammonia, welding fumes or food flavoring fumes) and respiratory infections can cause lung injury that leads to bronchiolitis obliterans. It can also be associated with rheumatoid arthritis and graft-versus-host disease following a lung or hematopoietic cell transplantation. While there is no way to reverse the disease, treatments are available that may stabilize or slow the progression. Another similarly named disease, bronchiolitis obliterans organizing pneumonia, is a completely different disease.

MalaCards based summary : Bronchiolitis Obliterans, also known as obliterative bronchiolitis, is related to cryptogenic organizing pneumonia and bronchiolitis. An important gene associated with Bronchiolitis Obliterans is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Azithromycin and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include Lung, lung and bone, and related phenotypes are homeostasis/metabolism and hematopoietic system

Disease Ontology : 12 A obstructive lung disease involving obstruction of the bronchioles due to inflammation and fibrosis which occurs as a complication of various lung conditions or physiological insults.

Wikipedia : 76 Bronchiolitis obliterans (BO), also known as popcorn lung and constrictive bronchiolitis, is a disease... more...

Related Diseases for Bronchiolitis Obliterans

Diseases related to Bronchiolitis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 410)
# Related Disease Score Top Affiliating Genes
1 cryptogenic organizing pneumonia 33.8 CXCL8 MMP9 TIMP1
2 bronchiolitis 31.9 CXCL8 IFNG IL10 IL17A IL6 TNF
3 pneumonia 31.9 CXCL8 IL10 IL6 TNF
4 hematopoietic stem cell transplantation 31.2 IFNG IL10 IL6 TNF
5 chronic graft versus host disease 30.8 IFNG IL10 TNF
6 respiratory failure 30.6 CXCL8 SCGB1A1 TNF
7 acute respiratory distress syndrome 30.5 CXCL8 IL6 TNF
8 aspergillosis 30.4 IFNG IL10 TNF
9 colitis 30.4 CXCL8 IFNG IL10 IL17A IL6 TNF
10 hyperlucent lung 30.4 IFNG IL10
11 graft-versus-host disease 30.4 GZMB IFNG IL10 IL6 TNF
12 ulcerative colitis 30.4 CXCL8 IFNG IL10 IL17A IL6 TNF
13 rheumatoid lung disease 30.4 IL17A TNF
14 arthritis 30.4 CXCL8 IFNG IL10 IL17A IL6 MMP9
15 viral infectious disease 30.2 CXCL8 IFNG IL10 IL6 TNF
16 arteries, anomalies of 30.2 IL6 MMP9 TNF
17 pulmonary edema 30.2 CXCL8 IL10 TNF
18 myasthenia gravis 30.2 IFNG IL10 TNF
19 cystitis 30.2 CXCL8 IL6 TNF
20 synovitis 30.2 CXCL8 IL6 TNF
21 pulmonary tuberculosis 30.2 IFNG IL10 TNF
22 psoriatic arthritis 30.2 IL17A IL6 TNF
23 human immunodeficiency virus infectious disease 30.1 IFNG IL10 IL6 TNF
24 pulmonary sarcoidosis 30.1 CXCR3 IFNG TNF
25 rheumatoid arthritis 30.1 CXCL8 IFNG IL10 IL17A IL6 MMP9
26 systemic lupus erythematosus 30.1 CXCL8 CXCR3 IFNG IL10 IL17A IL6
27 chlamydia 30.0 CXCL8 IFNG IL10 IL6 TNF
28 common variable immunodeficiency 30.0 IFNG IL10 IL6 TNF
29 adult respiratory distress syndrome 29.9 CXCL8 IL10 IL6 TNF
30 plasmodium vivax malaria 29.9 IFNG IL10 IL6 TNF
31 melioidosis 29.9 IFNG IL10 IL6 TNF
32 castleman disease 29.9 IL10 IL6 PPL
33 acquired immunodeficiency syndrome 29.9 IFNG IL10 IL6 TNF
34 extrinsic allergic alveolitis 29.8 CXCL8 CXCR3 IL10 IL6
35 mycoplasma pneumoniae pneumonia 29.8 IFNG IL10 IL17A IL6 TNF
36 lung disease 29.8 CXCL8 CXCR3 IL10 IL17A IL6 MMP8
37 asthma 29.7 CXCL8 IFNG IL10 IL17A IL6 MMP9
38 cytomegalovirus infection 29.7 CXCL8 IL6 TNF
39 acute graft versus host disease 29.7 GZMB IFNG IL10 TNF
40 inflammatory bowel disease 29.6 CXCL8 IFNG IL10 IL17A IL6 TNF
41 pulmonary disease, chronic obstructive 29.5 CXCL8 CXCR3 IL17A IL6 MMP9 SCGB1A1
42 pulmonary fibrosis, idiopathic 29.4 CXCL8 CXCR3 IFNG MMP9 PDGFB SCGB1A1
43 malaria 29.2 CXCL8 CXCR3 IFNG IL10 IL17A IL6
44 bronchiolitis obliterans with obstructive pulmonary disease 12.6
45 pemphigus 10.6
46 paraneoplastic pemphigus 10.6
47 lupus erythematosus 10.5
48 lymphoma 10.4
49 breast cancer 10.4
50 pneumothorax 10.4

Graphical network of the top 20 diseases related to Bronchiolitis Obliterans:



Diseases related to Bronchiolitis Obliterans

Symptoms & Phenotypes for Bronchiolitis Obliterans

MGI Mouse Phenotypes related to Bronchiolitis Obliterans:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.11 CXCR3 IFNG IL10 IL17A IL6 MMP8
2 hematopoietic system MP:0005397 10.06 CXCR3 IFNG IL10 IL17A IL6 MMP9
3 immune system MP:0005387 10.06 CXCR3 IFNG IL10 IL17A IL6 MMP8
4 cardiovascular system MP:0005385 10.03 CXCR3 IFNG IL10 IL6 MMP9 PDGFB
5 neoplasm MP:0002006 9.81 CXCR3 IFNG IL10 IL6 MMP8 MMP9
6 integument MP:0010771 9.8 EVPL IFNG IL10 IL6 MMP9 PDGFB
7 renal/urinary system MP:0005367 9.5 CXCR3 IFNG IL17A IL6 MMP9 PDGFB
8 respiratory system MP:0005388 9.32 CXCR3 IFNG IL10 IL17A IL6 MMP9

Drugs & Therapeutics for Bronchiolitis Obliterans

Drugs for Bronchiolitis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azithromycin Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 83905-01-5 55185 447043
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189
3
Montelukast Approved Phase 4,Phase 2 158966-92-8 5281040
4
Aztreonam Approved Phase 4 78110-38-0 5362041 5742832
5
Mechlorethamine Approved, Investigational Phase 4,Phase 3 51-75-2 4033
6
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
7
Prednisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 53-03-2 5865
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 46835353 6436030 5284616
9
Azathioprine Approved Phase 4,Phase 2 446-86-6 2265
10
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 104987-11-3 445643 439492
11
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
12
Macitentan Approved Phase 4 441798-33-0
13
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
15 Hormone Antagonists Phase 4,Phase 1,Phase 2,Not Applicable
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 1,Phase 2,Not Applicable
17 Hormones Phase 4,Phase 1,Phase 2,Not Applicable
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
20 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
21 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
22 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
23 glucocorticoids Phase 4,Phase 1,Phase 2,Not Applicable
24 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
25 Calciferol Phase 4
26 Bone Density Conservation Agents Phase 4
27 Ergocalciferols Phase 4
28 Vitamin D2 Phase 4
29 Olive Phase 4
30 Trace Elements Phase 4
31 Vitamins Phase 4
32 Micronutrients Phase 4
33 Respiratory System Agents Phase 4,Phase 2,Not Applicable
34 Leukotriene Antagonists Phase 4,Phase 2
35 Anti-Asthmatic Agents Phase 4,Phase 2,Not Applicable
36 Cysteinyl-leukotriene Phase 4
37 Parasympatholytics Phase 4
38 Tocolytic Agents Phase 4,Not Applicable
39 Adrenergic beta-Agonists Phase 4,Phase 2,Not Applicable
40 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Adrenergic Agonists Phase 4,Phase 2,Not Applicable
42 Adrenergic beta-2 Receptor Agonists Phase 4,Phase 2,Not Applicable
43 Cholinergic Agents Phase 4
44 Cholinergic Antagonists Phase 4
45 Albuterol Phase 4,Not Applicable
46 Autonomic Agents Phase 4,Phase 2,Not Applicable
47 Neurotransmitter Agents Phase 4,Phase 2,Not Applicable
48 Tiotropium Bromide Phase 4 136310-93-5
49 Bromides Phase 4
50 Adrenergic Agents Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Vitamin D in Bronchiolitis Obliterans Syndrome Completed NCT01212406 Phase 4 Vitamin D
2 Montelukast in Bronchiolitis Obliterans Syndrome Completed NCT01211509 Phase 4 Montelukast
3 Bronchodilator Responsiveness in Obliterative Bronchiolitis Completed NCT01112241 Phase 4 albuterol plus tiotropium
4 Azithromycin in Bronchiolitis Obliterans Syndrome Completed NCT01009619 Phase 4 Azithromycin;Placebo
5 Safety Study of Aztreonam Lysine for Inhalation (AZLI) in the Treatment of Early Bronchiolitis Obliterans Syndrome (BOS) Completed NCT01469364 Phase 4 Aztreonam Lysine for Inhalation (AZLI)
6 Use of Erythromycin in Mustard-Induced Bronchiolitis Completed NCT00367419 Phase 4 Erythromycin
7 Comparison of Sirolimus and Azathioprine in Lung Transplantation Completed NCT00321906 Phase 4 azathioprine;sirolimus
8 Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation Completed NCT01109160 Phase 4 Azithromycin Dihydrate
9 Macitentan in the Treatment of Organ Rejection After Lung Transplantation Not yet recruiting NCT02893176 Phase 4 macitentan;placebo (for macitentan)
10 Tacrolimus Versus Cyclosporine for Immunosuppression After Lung Transplantation Completed NCT01429844 Phase 3 Tacrolimus;Cyclosporine
11 Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation Completed NCT00755781 Phase 3 Cyclosporine Inhalation Solution (CIS)
12 Study Comparing Simulect Plus Standard Immunosuppression to Standard Immunosuppression Alone for the Prevention of Acute Rejection and Bronchiolitis Obliterans in Lung Transplant Completed NCT00188825 Phase 3 basiliximab
13 Use of Clarithromycin in Mustard-Induced Bronchiolitis Completed NCT00381147 Phase 3 Clarithromycin
14 Immunosuppressive Therapy With Certican (Everolimus) After Lung Transplantation Completed NCT00402532 Phase 3 Everolimus;Mycophenolatmofetil
15 Efficacy of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients Completed NCT01404325 Phase 3 standard therapy;Everolimus (RAD001) as add-on;RAD001
16 European Trial of Pirfenidone in BOS, A European Multi-center Study Recruiting NCT02262299 Phase 2, Phase 3 Pirfenidone;Placebo
17 Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children Recruiting NCT02426112 Phase 3 Azithromycin;Placebo
18 Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Active, not recruiting NCT01959100 Phase 3 Azithromycin;Placebo
19 A Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A Inhalation Solution in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Single Lung Transplant Not yet recruiting NCT03657342 Phase 3 Liposomal Cyclosporine A
20 A Clinical Trial to Demonstrate the Effectiveness and Safety of Liposomal Cyclosporine A Inhalation Solution in the Treatment of Bronchiolitis Obliterans Syndrome in Patients Post Double Lung Transplant Not yet recruiting NCT03656926 Phase 3 Liposomal Cyclosporine A
21 Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 1-2 Not yet recruiting NCT03283007 Phase 3 Nintedanib;Placebo
22 Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) Terminated NCT01439958 Phase 3 Inhalation
23 L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients Terminated NCT01334892 Phase 2, Phase 3 Cyclosporine Inhalation Solution
24 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
25 CIS001 Extension Study of Cyclosporine Inhalation Solution Terminated NCT00938236 Phase 3 Cyclosporine Inhalation Solution (CIS)
26 A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT Unknown status NCT01639261 Phase 2 Interferon gamma 1b
27 MSC for Treatment of Interstitial Lung Disease After Allo-HSCT Unknown status NCT02543073 Phase 1, Phase 2 AZM;Glucocorticoid
28 Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease Unknown status NCT00472225 Phase 2 Rituximab
29 Targeted Therapy of Bronchiolitis Obliterans Syndrome Completed NCT01307462 Phase 2 fluticasone propionate;montelukast sodium;azithromycin
30 Montelukast to Treat Bronchiolitis Obliterans Completed NCT00656058 Phase 2 Singulair (Montelukast Sodium)
31 Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation Completed NCT01560689 Phase 2 Budesonide/formoterol;Placebo
32 Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Completed NCT01287078 Phase 2 Cyclosporine Inhalation Solution
33 Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients Completed NCT01650545 Phase 1, Phase 2 Liposomal aerosol cyclosporine
34 Prospective Evaluation of the Efficacy of Budesonide/Formoterol in Bronchiolitis Obliterans in AHSCT Completed NCT00624754 Phase 2 Formoterol/Budesonide;lactose
35 Study of Enbrel (Etanercept) for the Treatment Sub-Acute Pulmonary Dysfunction After Allogeneic Stem Cell Transplant Completed NCT00141726 Phase 2 Etanercept
36 Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation Completed NCT00029328 Phase 1, Phase 2 etanercept
37 Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment Completed NCT00079183 Phase 2 sirolimus
38 Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT Completed NCT02036970 Phase 2 Bardoxolone methyl;Placebo
39 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Recruiting NCT01273207 Phase 2 Cyclosporine Inhalation Solution (CIS)
40 Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT) Recruiting NCT03674047 Phase 2 ruxolitinib
41 AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT02669251 Phase 1, Phase 2 AZD9668
42 Hp129 Xenon Imaging and BOS in Lung Transplantation Recruiting NCT03603899 Phase 1, Phase 2 Hp 129Xenon
43 Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant Recruiting NCT03330795 Phase 1, Phase 2
44 Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction Recruiting NCT02709343 Phase 2 Bone-marrow derived MSCs;Placebo
45 Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure Recruiting NCT03500731 Phase 1, Phase 2 Rituximab;Alemtuzumab;Fludarabine;Thiotepa;G-CSF;Hydroxyurea
46 A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD Active, not recruiting NCT01163786 Phase 2 Bortezomib
47 Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation Active, not recruiting NCT02614872 Phase 2 GLASSIA® and Institution standard of care (SOC)
48 Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases Enrolling by invitation NCT01852370 Phase 1, Phase 2
49 Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation Not yet recruiting NCT03805477 Phase 2 Nintedanib
50 Continuation of Nintedanib After Single Lung Transplantation in IPF Subjects Not yet recruiting NCT03562416 Phase 2 Nintedanib;Placebo Oral Tablet

Search NIH Clinical Center for Bronchiolitis Obliterans

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bronchiolitis Obliterans cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bronchiolitis Obliterans:
Mesenchymal stem cells for obliterative bronchiolitis
Embryonic/Adult Cultured Cells Related to Bronchiolitis Obliterans:
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: bronchiolitis obliterans

Genetic Tests for Bronchiolitis Obliterans

Anatomical Context for Bronchiolitis Obliterans

MalaCards organs/tissues related to Bronchiolitis Obliterans:

41
Lung, Bone, Bone Marrow, Heart, T Cells, B Cells, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Bronchiolitis Obliterans:
# Tissue Anatomical CompartmentCell Relevance
1 Lung Respiratory Bronchioles Cilliated Cells Affected by disease, potential therapeutic candidate

Publications for Bronchiolitis Obliterans

Articles related to Bronchiolitis Obliterans:

(show top 50) (show all 1315)
# Title Authors Year
1
Bronchiolitis Obliterans and Pulmonary Fibrosis After Sulfur Mustard Inhalation in Rats. ( 29314868 )
2018
2
Bronchiolitis obliterans syndrome susceptibility and the pulmonary microbiome. ( 29929823 )
2018
3
Bronchiolitis obliterans organizing pneumonia after stereotactic ablative radiation therapy for lung cancer: A case report. ( 29395853 )
2018
4
Bronchiolitis obliterans organising pneumonia as an initial manifestation in a patient with systemic lupus erythematosus: a rare presentation. ( 29804073 )
2018
5
High-Resolution CT Findings of Obstructive and Restrictive Phenotypes of Chronic Lung Allograft Dysfunction: More Than Just Bronchiolitis Obliterans Syndrome. ( 29792746 )
2018
6
Machine Learning Algorithms Utilizing Quantitative CT Features May Predict Eventual Onset of Bronchiolitis Obliterans Syndrome After Lung Transplantation. ( 29472146 )
2018
7
Bronchiolitis obliterans murine model induced by nitric acid aerosol inhalation: An economical and reproducible model. ( 29683731 )
2018
8
Montelukast for bronchiolitis obliterans syndrome after lung transplantation: A randomized controlled trial. ( 29624575 )
2018
9
Efficacy of high-dose steroids for bronchiolitis obliterans syndrome post pediatric hematopoietic stem cell transplantation. ( 29417689 )
2018
10
Radiological Improvement of Bronchiolitis Obliterans Following Hematopoietic Stem Cell Transplantation in a Patient Treated with Ruxolitinib. ( 29803525 )
2018
11
Impact of lung function on bronchiolitis obliterans syndrome and outcome after allogeneic hematopoietic cell transplantation with reduced intensity conditioning. ( 29964193 )
2018
12
Post-infectious bronchiolitis obliterans in children: is general quality of life the right measure? ( 29438684 )
2018
13
Home spirometry in bronchiolitis obliterans post allogeneic haematopoietic cell transplant. ( 29794130 )
2018
14
Postinfectious bronchiolitis obliterans ( 29775038 )
2018
15
Mycobacterium abscessus and massiliense lung infection during macrolide treatment for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. ( 28988958 )
2018
16
Evaluating for Bronchiolitis Obliterans with Low Attenuation CT 3D Reconstructions. ( 29406777 )
2018
17
High circulating CD4<sup>+</sup>CD25<sup>hi</sup>FOXP3<sup>+</sup> T-cell sub-population early after lung transplantation is associated with development of bronchiolitis obliterans syndrome. ( 29571601 )
2018
18
Mesalazine-induced Bronchiolitis Obliterans with Organizing Pneumonia in a young patient with Ulcerative Colitis. ( 29931114 )
2018
19
Bronchiolitis obliterans syndrome is associated with increased p-glycoprotein expression and loss of glucocorticoid receptor from steroid-resistant proinflammatory CD8<sup>+</sup>T cells. ( 29352737 )
2018
20
Bronchiolitis obliterans in a transplant-waitlisted patient with hepatorenal polycystic disease. ( 29907421 )
2018
21
Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome After Lung Transplantation. ( 29557913 )
2018
22
Extracorporeal Photopheresis Improves Survival in Hematopoietic Cell Transplant Patients with Bronchiolitis Obliterans Syndrome without Significantly Impacting Measured Pulmonary Functions. ( 29679771 )
2018
23
Bronchiolitis Obliterans without Joint Disease. A rare non-articular manifestation of Rheumatoid Arthritis ( 30547528 )
2018
24
Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy. ( 29998025 )
2018
25
Diagnosis and treatment of bronchiolitis obliterans syndrome accessible universally. ( 30038355 )
2018
26
Lung resident mesenchymal cells isolated from patients with the Bronchiolitis Obliterans Syndrome display a deregulated epigenetic profile. ( 30042393 )
2018
27
Comment on "Bronchiolitis Obliterans and Pulmonary Fibrosis after Sulfur Mustard Inhalation in Rats". ( 30067091 )
2018
28
Reply to: Comment on "Bronchiolitis Obliterans and Pulmonary Fibrosis after Sulfur Mustard Inhalation in Rats". ( 30067093 )
2018
29
Unicentric castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus. ( 30128272 )
2018
30
Factors Associated With Mortality and Response to Extracorporeal Photopheresis in Lung Allograft Recipients With Bronchiolitis Obliterans Syndrome. ( 30130331 )
2018
31
Lobe-wise assessment of lung volume and density distribution in lung transplant patients and value for early detection of bronchiolitis obliterans syndrome. ( 30150035 )
2018
32
Combined diffusing capacity for nitric oxide and carbon monoxide as predictor of bronchiolitis obliterans syndrome following lung transplantation. ( 30200966 )
2018
33
Impaired bone marrow B-cell development in mice with a bronchiolitis obliterans model of cGVHD. ( 30228128 )
2018
34
Clinical features of postinfectious bronchiolitis obliterans in children undergoing long-term nebulization treatment. ( 30269305 )
2018
35
The efficacy of extracorporeal photopheresis to arrest bronchiolitis obliterans in lung allograft recipients was compared between two automated photopheresis instruments. ( 30312482 )
2018
36
Case presentation: persistent adenovirus B3 infections associated with bronchiolitis obliterans treated with cidofovir in a child with mosaic tetrasomy 9p. ( 30348093 )
2018
37
Bronchiolitis obliterans syndrome-free survival after lung transplantation: An International Society for Heart and Lung Transplantation Thoracic Transplant Registry analysis. ( 30391193 )
2018
38
HMGB1 blockade significantly improves luminal fibrous obliteration in a murine model of bronchiolitis obliterans syndrome. ( 30508580 )
2018
39
Post-infectious bronchiolitis obliterans. ( 30548423 )
2018
40
Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: the effect of NOD2/CARD15 mutations in a Tunisian population. ( 30552907 )
2018
41
Depletion of Airway Submucosal Glands and TP63+KRT5+ Basal Cells in Obliterative Bronchiolitis. ( 29236513 )
2018
42
Inert Gas Washout in Bronchiolitis Obliterans Following Hematopoietic Cell Transplantation. ( 29275133 )
2018
43
Tocilizumab Cannot Prevent the Development of Bronchiolitis Obliterans in Patients With Castleman Disease-Associated Paraneoplastic Pemphigus. ( 29389687 )
2018
44
Diacetyl and occupational bronchiolitis obliterans: Comments on Rose, CS: Early detection, clinical diagnosis and management of lung disease from exposure to diacetyl, toxicology (2017), https://doi.org/10.1016/j.tox.2017.03.019. ( 29054810 )
2017
45
Blood Gene Expression Predicts Bronchiolitis Obliterans Syndrome. ( 29375549 )
2017
46
Serum miRNAs as potential biomarkers for the bronchiolitis obliterans syndrome after lung transplantation. ( 28457921 )
2017
47
The role of epithelial-mesenchymal transition in the post-lung transplantation bronchiolitis obliterans. ( 29262833 )
2017
48
Chest computed tomography in bronchiolitis obliterans after bone marrow transplantation. ( 28670041 )
2017
49
Achievement of the longest survival of paraneoplastic pemphigus with bronchiolitis obliterans associated with follicular lymphoma using R-CHOP chemotherapy. ( 28791608 )
2017
50
Cathelicidin (LL-37) and human I^2-defensin levels of children with post-infectious bronchiolitis obliterans. ( 26073571 )
2017

Variations for Bronchiolitis Obliterans

Expression for Bronchiolitis Obliterans

Search GEO for disease gene expression data for Bronchiolitis Obliterans.

Pathways for Bronchiolitis Obliterans

Pathways related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 CXCL8 IFNG IL10 IL17A IL6 MMP8
2
Show member pathways
13.66 CXCL8 CXCR3 IFNG IL10 IL17A IL6
3
Show member pathways
13.52 CXCL8 IFNG IL10 IL17A IL6 PDGFB
4
Show member pathways
13.39 CXCL8 CXCR3 IL10 IL17A IL6 PDGFB
5
Show member pathways
13.34 CXCL8 IFNG IL10 IL17A IL6 MMP9
6
Show member pathways
13.28 CXCL8 CXCR3 IL10 IL17A IL6 PDGFB
7
Show member pathways
13.02 CXCL8 IL6 MMP9 PDGFB TNF
8
Show member pathways
12.99 CXCL8 IFNG IL10 IL6 TNF
9
Show member pathways
12.88 CXCL8 GZMB IFNG IL10 IL17A IL6
10 12.83 CXCL8 IFNG IL6 MMP9 PDGFB
11
Show member pathways
12.61 IFNG IL10 IL17A IL6 TNF
12 12.57 GZMB IFNG IL10 IL17A TNF
13
Show member pathways
12.53 IFNG IL10 IL17A IL6 PDGFB TIMP1
14
Show member pathways
12.44 IFNG IL10 IL17A IL6 TNF
15
Show member pathways
12.39 IFNG IL10 IL6 PDGFB
16
Show member pathways
12.32 CXCL8 IFNG IL6 TNF
17
Show member pathways
12.32 CXCL8 IFNG IL17A IL6 MMP9 TNF
18 12.27 CXCL8 GZMB IL6 MMP9
19 12.25 IFNG IL10 IL6 TNF
20
Show member pathways
12.21 CXCL8 IFNG IL6 TNF
21 12.2 IFNG IL6 MMP9 TNF
22 12.19 CXCL8 IL10 IL6 TNF
23
Show member pathways
12.13 CXCL8 IFNG IL10 IL17A IL6 PDGFB
24 12.11 IFNG MMP9 PDGFB TNF
25
Show member pathways
12.1 IFNG IL10 IL17A IL6 TNF
26
Show member pathways
12.06 IFNG IL6 MMP9 TNF
27 12.04 CXCL8 IFNG IL6 MMP9 TNF
28
Show member pathways
12.03 CXCL8 IFNG IL10 IL17A IL6 PDGFB
29 12.02 IFNG IL10 IL6 TNF
30 11.95 IL6 MMP9 TNF
31 11.93 CXCL8 IFNG IL6
32
Show member pathways
11.93 MMP8 MMP9 TIMP1 TNF
33 11.91 IFNG IL6 TIMP1
34 11.9 CXCL8 IL6 TNF
35 11.9 CXCL8 IFNG IL10 IL6 TNF
36
Show member pathways
11.87 CXCL8 IL17A IL6
37 11.86 IFNG IL10 IL6
38 11.85 CXCL8 IFNG IL17A IL6 TNF
39 11.83 CXCL8 IFNG IL6
40 11.81 CXCL8 IFNG IL6
41 11.8 CXCL8 IL10 IL6 TNF
42 11.79 IFNG IL10 IL6 TNF
43
Show member pathways
11.78 CXCL8 IFNG TNF
44 11.7 CXCL8 IL6 MMP9
45 11.67 CXCL8 MMP9 TIMP1
46
Show member pathways
11.67 GZMB IFNG TNF
47 11.64 CXCR3 GZMB IFNG IL10 IL17A TNF
48
Show member pathways
11.63 CXCL8 IFNG IL6 MMP9 TNF
49 11.62 CXCL8 IFNG IL6
50 11.62 CXCL8 IL6 TNF

GO Terms for Bronchiolitis Obliterans

Cellular components related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CXCL8 IFNG IL10 IL17A IL6 MMP8
2 extracellular space GO:0005615 9.36 CXCL8 IFNG IL10 IL17A IL6 MMP8

Biological processes related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 IFNG IL6 MMP8 PDGFB TNF
2 negative regulation of gene expression GO:0010629 9.93 IFNG MMP8 PDGFB TNF
3 cellular response to lipopolysaccharide GO:0071222 9.85 CXCL8 IL10 IL6 TNF
4 inflammatory response GO:0006954 9.85 CXCL8 CXCR3 IL10 IL17A IL6 TNF
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.83 IL10 IL6 TNF
6 wound healing GO:0042060 9.82 EVPL PPL TIMP1
7 immune response GO:0006955 9.8 CXCL8 CXCR3 IFNG IL10 IL17A IL6
8 extracellular matrix disassembly GO:0022617 9.79 MMP8 MMP9 TIMP1
9 positive regulation of interleukin-6 production GO:0032755 9.77 IL6 MMP8 TNF
10 humoral immune response GO:0006959 9.77 IFNG IL6 TNF
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 IL6 PDGFB TNF
12 response to organic substance GO:0010033 9.73 IL10 SCGB1A1 TIMP1 TNF
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.71 IFNG MMP8 TNF
14 response to glucocorticoid GO:0051384 9.71 IL10 IL6 SCGB1A1 TNF
15 embryonic digestive tract development GO:0048566 9.67 CXCL8 TNF
16 positive regulation of glial cell proliferation GO:0060252 9.66 IL6 TNF
17 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.66 IFNG TNF
18 negative regulation of growth of symbiont in host GO:0044130 9.65 IL10 TNF
19 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL10 TNF
20 response to molecule of bacterial origin GO:0002237 9.64 CXCL8 IL10
21 negative regulation of lipid storage GO:0010888 9.63 IL6 TNF
22 positive regulation of osteoclast differentiation GO:0045672 9.63 IFNG IL17A TNF
23 endothelial cell apoptotic process GO:0072577 9.62 IL10 TNF
24 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.62 IL10 TIMP1
25 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.62 IL10 MMP9 PDGFB TNF
26 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 IL10 TNF
27 positive regulation of interleukin-23 production GO:0032747 9.58 IFNG IL17A
28 regulation of neuroinflammatory response GO:0150077 9.57 MMP8 MMP9
29 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 IFNG TNF
30 receptor biosynthetic process GO:0032800 9.51 IL10 TNF
31 cytokine-mediated signaling pathway GO:0019221 9.5 CXCL8 IL10 IL17A IL6 MMP9 TIMP1
32 regulation of microglial cell activation GO:1903978 9.49 MMP8 TNF
33 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 IFNG TNF
34 positive regulation of neuroinflammatory response GO:0150078 9.33 IL6 MMP8 TNF
35 regulation of signaling receptor activity GO:0010469 9.23 CXCL8 IFNG IL10 IL17A IL6 PDGFB

Molecular functions related to Bronchiolitis Obliterans according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL10 IL6 PDGFB TIMP1
2 cytokine activity GO:0005125 9.17 CXCL8 IFNG IL10 IL17A IL6 TIMP1

Sources for Bronchiolitis Obliterans

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....